These findings indicate that leukemia cells from distinct TP53 backgrounds have an overlapping overall response landscape following treatment with BH3 mimetics and thus provide a rationale for using BH3 mimetics targeting both BCL-2 and MCL-1 to effectively treat TP53-deficient and -mutant leukemia cells. Here, BCL2 is linked to leukemia.